Canada - English - Health Canada

chanelle pharmaceuticals manufacturing limited - meloxicam - solution - 5mg - meloxicam 5mg - cats; dogs

Canada - English - Health Canada

chanelle pharmaceuticals manufacturing limited - meloxicam - solution - 5mg - meloxicam 5mg - cats; dogs

Canada - English - Health Canada

norbrook laboratories ltd. - meloxicam - solution - 5mg - meloxicam 5mg - cats; dogs

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - indications as at 17 jan 2005 : tachycardias, such as paroxysmal supraventricular tachycardia, atrial fibrillation with rapid ventricular response, (except in wpw syndrome, see "precautions"), atrial flutter with rapid conduction, extrasystoles. for the prophylaxis and/or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia, respectively. acute hypertension. acute coronary insufficiency.,tachycardias, such as paroxysmal supraventricular tachycardia, atrial fibrillation with rapid ventricular response, (except in wpw syndrome, see "precautions"), atrial flutter with rapid conduction, extrasystoles. for the prophylaxis and/or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia, respectively. acute hypertension. acute coronary insufficiency.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg;   - capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg   excipient: gelatin indigo carmine iron oxide red magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base; levodopa 200mg;   - capsule - 250 mg - active: benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base levodopa 200mg   excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - capsule - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: gelatin indigo carmine iron oxide black magnesium stearate mannitol microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - dispersible tablet - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: citric acid magnesium stearate maize starch microcrystalline cellulose - madopar rapid is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism. madopar rapid is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit "delayed on" or "wearing off" phenomena.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg;   - modified release capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg   excipient: calcium hydrogen phosphate dihydrate gelatin hydrogenated vegetable oil hypromellose indigo carmine iron oxide yellow magnesium stearate mannitol povidone purified talc titanium dioxide - madopar hbs is indicated for patients presenting with all types of fluctuation in response, especially those related to fluctuations in plasma levels (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - aminophylline - solution for injection - aminophylline 250 mg / 10 ml - aminophylline - aminophylline - for symptomatic relief or prevention of bronchial asthma and for treatment of reversible bronchospasm associated with chronic bronchitis and emphysema.